Patients who have had an acute myocardial infarction and are treated with a lower dose of beta blockers than used in clinical trials show similar or better survival than those given higher doses, a new study has found.
The multicentre study, published in the Journal of the American College of Cardiology, enrolled 7057 consecutive patients with acute myocardial infarction at 26 centres in the United States and Canada.
1 Researchers looked at the dose of beta blocker given to patients when they were discharged from hospital and followed them up for survival rates at two years.
Results showed that the vast majority (91.5%) of the 6682 patients with complete follow-up data were discharged from hospital on a beta blocker. But the mean dose was 38.1% lower than that used in randomised clinical trials.
Patients discharged on a beta blocker at any dose had a significantly lower mortality rate than those not given this type of drug (P<0.0002). But the risk of death at two years decreased with lower doses of beta blockers.
Patients given >25% to 50% of the beta blocker dose used in clinical trials had 4% lower mortality at two years than those given a higher dose (>50%), after adjusting for potentially confounding variables (hazard ratio 0.963 (95% confidence interval 0.765 to 1.213)). The reduction in risk of death was even greater, at around 20%, in patients discharged from hospital on >12.5% to 25% of the trial dose of beta blocker (0.799 (0.635 to 1.005)) and in those given >0% to 12.5% of the dose (0.862 (0.677 to 1.098)).
The researchers were very surprised by the findings. Lead author Jeffrey Goldberger, from Northwestern University in Chicago, Illinois, launched the study when he discovered that patients who had had myocardial infarctions were being treated with lower doses of beta blockers than used in clinical trials.
"We set out on a mission to show [that] if you treat patients with the doses that were used in the clinical trials, they will do better," he explained. "We expected to see patients treated with the lower doses to have worse survival. We were shocked to discover they survived just as well, and possibly even better."
The research group said that its findings provided the rationale for further research to establish the dose of beta blocker that gives optimal benefit after a myocardial infarction. 
